Correlation of deregulated like-acetylglucosaminyl transferase and aberrant α-dystroglycan expression with human tongue cancer metastasis

J Oral Maxillofac Surg. 2014 Jun;72(6):1106-18. doi: 10.1016/j.joms.2013.12.031. Epub 2014 Jan 15.

Abstract

Purpose: The present study examined the correlation of α-dystroglycan (α-DG) expression and like-acetylglucosaminyl transferase (LARGE) with metastasis of human tongue cancer.

Materials and methods: Fifty human tongue cancer tissues and 2 tongue squamous cell carcinoma cell lines (CAL27 and SCC4) were involved. Immunohistochemistry was used to detect the expression of α-DG and LARGE. Methylation-specific polymerase chain reaction was performed to assess the methylation status of the LARGE gene promoter. CAL27 and SCC4 cells were transfected with exogenous LARGE and treated with 5-aza-2'-deoxycytidine (Aza-dC), respectively. Glycol sites of α-DG were detected by western blotting. In addition, the laminin overlay assay, cell adhesion assay, and invasion assay were performed.

Results: Immunohistochemical results showed that decreased expression of VIA4-1 and IIH6 (antibodies that recognize the glycol sites of α-DG) were correlated with the lymph node metastasis of tongue cancer (n = 50; P = .016 and .025, respectively). Decreased LARGE expression and hypermethylation of the LARGE gene promoter were correlated with lymph node metastasis and α-DG glycosylation in human tongue cancer (n = 50; P = .043 and .015 respectively). In addition, LARGE overexpression and Aza-dC treatment actively led to restoration of functional α-DG expression, elevation of laminin binding, and decrease of migratory ability in cancer cells.

Conclusion: The results suggested that absent α-DG expression and LARGE deregulation were closely associated with nodal metastasis of tongue cancer. Aberrant α-DG expression and glycosylation were attributed at least in part to the abnormal epigenetic modification of LARGE, especially the hypermethylation of its promoter.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Azacitidine / analogs & derivatives
  • Azacitidine / pharmacology
  • Carcinoma, Squamous Cell / pathology
  • Carcinoma, Squamous Cell / secondary*
  • Cell Adhesion
  • Cell Line, Tumor
  • Cell Movement / drug effects
  • DNA Methylation
  • DNA Modification Methylases / antagonists & inhibitors
  • Decitabine
  • Dystroglycans / analysis*
  • Dystroglycans / genetics
  • Enzyme Inhibitors / pharmacology
  • Epigenesis, Genetic / genetics
  • Female
  • Gene Expression Regulation, Neoplastic / genetics
  • Glycosylation
  • Humans
  • Immunohistochemistry
  • Laminin / analysis
  • Lymphatic Metastasis / pathology
  • Male
  • Middle Aged
  • N-Acetylglucosaminyltransferases / analysis*
  • N-Acetylglucosaminyltransferases / genetics
  • Neoplasm Invasiveness
  • Neoplasm Staging
  • Plasmids / genetics
  • Promoter Regions, Genetic / genetics
  • Tongue Neoplasms / pathology*
  • Transfection

Substances

  • DAG1 protein, human
  • Enzyme Inhibitors
  • Laminin
  • Dystroglycans
  • Decitabine
  • DNA Modification Methylases
  • LARGE1 protein, human
  • N-Acetylglucosaminyltransferases
  • Azacitidine